Linifanib
Linifanib (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib shows prominent antitumor activity. Linifanib has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib is a specific miR-10b inhibitor that blocks miR-10b biogenesis[1][2].
Product Specifications
CAS Number
796967-16-3
Product Name Alternative
ABT-869; AL-39324
UNSPSC
12352005
Hazard Statement
H361, H372, H410
Target
Apoptosis; Autophagy; c-Fms; c-Kit; FLT3; PDGFR; VEGFR
Type
Reference compound
Related Pathways
Apoptosis; Autophagy; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/linifanib.html
Purity
99.72
Solubility
DMSO : 13.16 mg/mL (ultrasonic)
Smiles
O=C(NC1=CC=C(C2=C3C(N)=NNC3=CC=C2)C=C1)NC4=C(C=CC(C)=C4)F
Molecular Formula
C21H18FN5O
Molecular Weight
375.40
Precautions
H361, H372, H410
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
PDGFRβ; VEGFR1/Flt-1; VEGFR2/KDR/Flk-1
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
TACSTD2 / TROP2 (Epithelial Marker) (TACSTD2/2151), CF488A conjugate, 0.1mg/mL
